<DOC>
	<DOCNO>NCT02498886</DOCNO>
	<brief_summary>At MRC Human Nutrition Research , investigator develop engineer analogue ferritin-core safe effective iron supplementation . Iron hydroxide adipate tartrate ( IHAT ) tartrate-modified , nano-disperse Fe ( III ) oxo-hydroxide , form adipate buffer , similar functional property small primary particle size ( ~2 nm ) iron find ferritin core ; good mimic iron absorption food non-physiological bolus dos ferrous sulphate currently use . This exploratory study test hypothesis IHAT equivalent bioavailability ferrous sulphate produce less harmful post-ingestion rise transferrin saturation . The design 3-arm ( IDA , non-IDA IDA-IHAT new manufacture ) , crossover , randomise , single-dose study . Primary endpoint : Relative bioavailability value IHAT versus ferrous sulphate . This determine red blood cell incorporation isotope-labelled iron 14 day follow single oral dose . Secondary endpoint : Serum iron 0 , 2 , 4 , 6 hour follow single dose iron compound . Transferrin saturation 0 , 2 , 4 , 6 hour follow single dose iron compound . Plasma 58Fe 57Fe 0 , 2 , 4 , 6 hour . Pathogen growth use ex vivo assay serum collect subject 0 , 2 , 4 6 hour follow single dose .</brief_summary>
	<brief_title>IHAT Absorption Kinetics</brief_title>
	<detailed_description>The study 's main hypothesis IHAT bioavailable pre-menopausal anaemic Gambian woman lead low serum iron transferrin saturation increase equivalent dose ferrous sulphate . Furthermore , investigator hypothesize IHAT produce less harmful post-ingestion rise transferrin saturation , i.e . serum collect subject follow single dose IHAT promote less pathogen growth ex vivo assay collect follow equivalent dose ferrous sulphate . Finally , base previous animal data [ 5 ] , investigator hypothesize IHAT absorption significantly high anaemic woman compare non-anaemic woman , case ferrous sulphate . This study cross-over , single-dose comparison ferrous sulphate ( standard care ) anaemic non-anaemic woman . The iron single dosage compound 60mg elemental iron equivalent compound label stable iron isotope . Outcomes : red blood cell incorporation label iron , serum iron , transferrin saturation pathogen growth ex vivo serum assay . Primary objective : To determine iron bioavailability ( i.e . red blood cell incorporation ) single dose IHAT versus ferrous sulphate pre-menopausal Gambian woman . Secondary objective : To determine serum iron absorption follow single dose IHAT versus ferrous sulphate pre-menopausal Gambian woman . To evaluate single-dose IHAT produce less harmful post-ingestion rise transferrin saturation serum iron ferrous sulphate . Each compound label stable isotope Fe absorption determine red blood cell incorporation stable isotope 14 day single dose . This study effectively Phase 0 study ( pharmacokinetics ) small number iron absorption varies individual individual , depend body iron need gastrointestinal digestion issue , accurate use study subject control . Therefore , subject ingest IHAT one study day active treatment comparator separate day . The 2 study visit need 14 day apart allow red blood cell incorporation stable iron isotope use label iron material . This method gold standard determine relative bioavailability value ( RBV ) novel iron compound ( i.e . relation ferrous sulphate absorption ) allow accurate determination RBV IHAT otherwise would possible use parallel study design small number .</detailed_description>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>Premenopausal woman apparently healthy ( judge study nurse screen day ) normal CRP ( measure screening ) . Nonpregnant ( test rapid pregnancy test ) nonlactating woman . IDA arm : 9≤Hb≤11 g/dL ferritin≤ 15 ng/ml NonIDA arm : Hb &gt; 11 g/dL ferritin &gt; 15 ng/ml . Malaria infection Severe anaemia ( Hb &lt; 9 g/dL ) CRP &gt; 5 mg/L Chronic disease Currently participate iron intervention study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>